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Abstract
Background: In experimental autoimmune encephalomyelitis (EAE), deletion of transient receptor potential
melastatin 4 (Trpm4) and administration of glibenclamide were found to ameliorate disease progression, prompting
speculation that glibenclamide acts by directly inhibiting Trpm4. We hypothesized that in EAE, Trpm4 upregulation
is accompanied by upregulation of sulfonylurea receptor 1 (Sur1) to form Sur1-Trpm4 channels, which are highly
sensitive to glibenclamide, and that Sur1-Trpm4 channels are required for EAE progression.
Methods: EAE was induced in wild-type (WT) and Abcc8−/− mice using myelin oligodendrocyte glycoprotein
35–55 (MOG35–55). Lumbar spinal cords were examined by immunohistochemistry, immuno-Förster resonance
energy transfer (immunoFRET), and co-immunoprecipitation for Sur1-Trpm4. WT/EAE mice were administered with
the Sur1 inhibitor, glibenclamide, beginning on post-induction day 10. Mice were evaluated for clinical function,
inflammatory cells and cytokines, axonal preservation, and white matter damage.
Results: Sur1-Trpm4 channels were upregulated in EAE, predominantly in astrocytes. The clinical course and
severity of EAE were significantly ameliorated in glibenclamide-treated WT/EAE and in Abcc8−/−/EAE mice. At
30 days, the lumbar spinal cords of glibenclamide-treated WT/EAE and Abcc8−/−/EAE mice showed significantly
fewer invading immune cells, including leukocytes (CD45), T cells (CD3), B cells (CD20) and macrophages/microglia
(CD11b), and fewer cells expressing pro-inflammatory cytokines (TNF-α, IFN-γ, IL-17). In both glibenclamide-treated
WT/EAE and Abcc8−/−/EAE mice, the reduced inflammatory burden correlated with better preservation of myelin,
better preservation of axons, and more numerous mature and precursor oligodendrocytes.
Conclusions: Sur-Trpm4 channels are newly upregulated in EAE and may represent a novel target for
disease-modifying therapy in multiple sclerosis.
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Background
Multiple sclerosis (MS) is an autoimmune disease
marked by chronic inflammation, demyelination, and
neurodegeneration of the central nervous system (CNS)
that causes neurological disability in young and middle-
aged adults [1, 2]. MS has no known cure, and patients
suffer from progressive disability due to irreversible
neurological damage. MS and its principal animal model,
experimental autoimmune encephalomyelitis (EAE), are
characterized by myelin-specific autoreactive T cells that
enter the CNS and initiate inflammation and tissue dam-
age leading to oligodendrocyte cell death, axonal demye-
lination, and neuronal degeneration [3]. Inflammation is
perpetuated by both infiltrating immune cells and by
astrocytes [4–9]. Of the currently approved disease-
modifying therapies for MS, most target immune cells
or a pro-inflammatory cytokine [10], with the only ex-
ception being fingolimod (FTY720), which has effects
directly on astrocytes [11, 12].
Emerging evidence indicates that transient receptor
potential melastatin 4 (Trpm4) plays a crucial role in the
pathophysiology of various CNS injuries. When upregu-
lated and activated, Trpm4 contributes to the formation
of cytotoxic edema, and it functions as an end-execu-
tioner in accidental necrotic death induced by Ca2+ over-
load, adenosine triphosphate (ATP) depletion, or reactive
oxygen species [13, 14]. Trpm4 is upregulated in micro-
vascular endothelial cells, neurons, and glial cells in pre-
clinical rat models of stroke, spinal cord injury, and
subarachnoid hemorrhage [15–19].
Recently, Schattling et al. [20] implicated Trpm4 up-
regulation in the pathophysiology of EAE and showed
that Trpm4 deletion was associated with reduced disease
severity and improved recovery following EAE induction.
They also showed that glibenclamide ameliorates clinical
signs of EAE, and they speculated that the salutary ef-
fects of glibenclamide were due to direct blockade of
Trpm4 [20]. However, given the low potency of gliben-
clamide inhibition of Trpm4 [17], a direct effect of glib-
enclamide on Trpm4 seems unlikely.
Sulfonylurea receptor 1 (Sur1) is an ATP-binding cas-
sette transporter family member that functions as a
regulatory subunit when it co-assembles with heterol-
ogous pore-forming subunits to form cation channels.
The most widely recognized association is with the
ATP-sensitive K+ channel, Kir6.2, with which it forms
Sur1-Kir6.2 (KATP) channels that are constitutively
expressed in pancreatic β cells and are linked to diabetes
mellitus [21–23]. Sur1 also associates with Trpm4 to
form Sur1-Trpm4 channels that are transcriptionally up-
regulated in the brain and spinal cord following ische-
mic, traumatic, and inflammatory CNS injuries [17–19].
A crucial property of the Sur1-Trpm4 channel is that
both subunits, Sur1 and Trpm4, must be upregulated
and functional for the manifestation of its pathological
effects, with deletion or pharmacological blockade of
either subunit resulting in equivalent abrogation of in-
jury severity [24].
We hypothesized that in EAE, Trpm4 upregulation, as
reported by Schattling et al. [20], is accompanied by up-
regulation of Sur1, that the two proteins co-assemble to
form Sur1-Trpm4 channels (which are highly sensitive
to glibenclamide [17]), and that Sur1-Trpm4 channels,
rather than Trpm4 channels alone, are required for dis-
ease progression and for manifestation of glibenclamide
sensitivity in EAE. Here, we assessed this hypothesis in a
murine EAE model using gene silencing and pharmaco-
logical inhibition of Sur1.
Methods
Murine EAE model
All experiments were conducted in accordance with the
guidelines of the National Institutes of Health and under
a protocol approved by the Institutional Animal Care
and Use Committee of the University of Maryland
School of Medicine. Female C57BL/6 J mice were ob-
tained from The Jackson Laboratory (Bar Harbor, ME).
Abcc8−/− mice, obtained as described [25], exhibited
neurological function, gait, and spinal cord histology
indistinguishable from WT. Mice were housed under
pathogen-free conditions in the animal facility of the
University of Maryland School of Medicine.
EAE was induced in female WT and Abcc8−/− mice at
8 weeks of age, as described [26, 27]. EAE was induced
with MOG35–55 peptide (Biomer Technology, Pleasanton,
CA, USA) in complete Freund’s adjuvant (Sigma-Aldrich,
St Louis, MO) containing Mycobacterium tuberculosis
(H37RA, Difco Laboratories, Detroit, MI). Mice were im-
munized by subcutaneous injection in the flank regions
(left and right sides) with 200 μL total of an emulsion of
MOG35–55 peptide (200 μg in 100 μL PBS plus 100 μL of
complete Freund’s adjuvant containing 0.4 mg of heat-
inactivated M. tuberculosis). Each mouse then received
400 ng of pertussis toxin (List Biological Laboratories)
intraperitoneally (IP) on post-induction day (pid) 0 and
pid-2.
Glibenclamide treatment
After the onset of clinical symptoms (>20 % of WT/EAE
mice with clinical scores of 1 or greater; pid-10), 10 μg
glibenclamide was administered daily by IP injection to
WT/EAE mice in the treatment group until the end of
the experiment (pid-30). A stock solution of glibencla-
mide was prepared by placing 25 mg of glibenclamide
(#G2539; meets USP testing; Sigma, St. Louis, MO) into
10 mL dimethyl sulfoxide (DMSO). We diluted 200 μL
of this solution in 9.8 mL PBS; mice received 100 μL of
this solution.
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Clinical evaluation
Scoring of disease severity was carried out as described
[26, 27]. From pid-0 onwards, mice were assessed daily
for signs of paralysis by two independent observers in a
blinded fashion. Mice were assigned a clinical score of
increasing severity: 1, limp tail; 2, hind limb paresis; 3,
complete hind limb paralysis; 4, hind limb paralysis and
body/front limb paresis/paralysis; 5, moribund. End
point evaluation included mean severity of disease
over time and mean day of disease onset (first day of
score >0). Paralyzed mice (scores 3 and 4) were moved to
individual cages where food and water were placed at cage
floor level. The weight of EAE mice was measured every
2 days and mice were euthanized if there was a loss of
more than 20 % in weight or if they become dehydrated.
Histology, immunochemistry, and immunoFRET
On pid-10 or pid-30, mice were euthanized and trans-
cardially perfused with NS (10 ml) followed by 10 %
neutral buffered formalin (15 ml). The spinal cords were
removed, and 7 μm cryosections or paraffin sections
were prepared from the lumbar region.
Fluorescence immunohistochemistry and immuno-
Förster resonance energy transfer (immunoFRET) were
performed on cryosections from pid-10 and pid-30 using
custom anti-Sur1 and anti-Trpm4 antibodies, as described
[17]. Controls for immunoFRET included omission of one
of the two primary antibodies. Co-localization analysis
was performed using the algorithm in Nikon NIS imaging
software, based on regions of interest (400 × 200 μm) posi-
tioned in white matter. Specific signals were defined as
fluorescence intensity twice that of background. Co-
localization of fluorescence signals in double immuno-
labeled sections was computed as Pearson’s correlation
coefficient [28].
Paraffin sections from pid-30 mice were stained with
hematoxylin and eosin (H&E) (for inflammatory cell
infiltrates) or Luxol fast blue (LFB) (for demyelination)
following standard protocols. Axonal loss was deter-
mined by silver nitrate (AgNO3) staining using Hito
Bielschowsky OptimStain Kit (#HTKNS1126, Hitobiotec
Inc., Wilmington, DE, USA). Slides were examined using
bright-field microscopy.
Chromagen immunohistochemistry was performed on
paraffin sections from pid-30, as described [29, 30],
using VECTASTAIN Elite ABC Kits (#PK-6100) and
Mouse on Mouse (M.O.M.) Elite Peroxidase Kit (#PK-
2200) (Vector Laboratories, Burlingame, CA). Primary
antibodies were directed against the following: CD45
(1:1500; #ab10558; Abcam, Cambridge, MA); CD3
(1:200; #ab5690; Abcam); CD20 (1:100; #sc-7735; Santa
Cruz Biotechnology, Santa Cruz, CA); CD11b (1:800;
#NB110-89474; Novus Biologicals, Littleton, CO); TNF-α
(1:500; #sc-1350; Santa Cruz Biotechnology); IFN-γ
(1:100; #bs-0480R; Bioss, Woburn, MA); IL-17 (1:50; #sc-
7927; Santa Cruz Biotechnology); IL-10 (1:50; #sc-1783;
Santa Cruz Biotechnology); MBP (1:500; #ab40390;
Abcam); CNPase (1:1000; #MAB326; EMD Millipore,
Billerica, MA); Olig-2 (1:2000; #MABN50; EMD Millipore);
PDGFR-α (1:500; #sc-338; Santa Cruz Biotechnology); and
SMI-312 (1:1000; #SMI-312R; Covance Inc., Gaithersburg,
MD). Nuclei were counterstained with hematoxylin. The
specificity of the immunostaining for all proteins was tested
in control slides by incubation with pre-immune serum or
after pre-adsorption of the antibody with the respective
peptides used as immunogens. Slides were examined using
bright-field microscopy.
Quantification of tissue stains and of chromagen
immunolabelings was performed by blinded observers
using Image J software (NIH, USA). Tissue stains and
markers (H&E, LFB, MBP, CNPase, SMI312, AgNO3)
were quantified by counting the number of positive/
negative quadrants and expressing the percentage over
the total number of quadrants examined. All cell label-
ing experiments were quantified based on an analysis of
8–10 fields per section, randomly positioned in white
matter (CD45, CD3, CD20, CD11b, TNF-α, IFN-γ, IL-17,
and Olig-2) or in tissues surrounding the central canal
(PDGFR-α), with each field being 435 × 325 μm.
Co-immunoprecipitation
Immunoblot and co-immunoprecipitation were performed
on lumbar spinal cord tissues from pid-30 using custom
anti-Sur1 and anti-Trpm4 antibodies, as described [17].
Statistical analysis
Statistical analyses were performed using Prism software
(GraphPad, San Diego, CA). Data are shown as mean ±
SEM. Statistical significance between groups was deter-
mined using one-way analysis of variance (one-way
ANOVA) with Fisher’s post-hoc comparisons. In all ex-
periments, P < 0.05 was considered to be statistically
significant.
Results
Sur1-Trpm4 heteromers in EAE mice
EAE was induced in WT and Abcc8−/− mice using
MOG35–55. Tissues from the lumbar region of the spinal
cord, where the disease is most prominent [31], were ex-
amined at pid-10 and pid-30. Tissues were immunola-
beled for Sur1, Trpm4, and cell-specific markers.
In white matter, Sur1 was not detected in normal WT
controls (without EAE induction) (Fig. 1a). Modest Sur1
immunolabeling was present in the white matter of WT/
EAE mice on pid-10, whereas by pid-30, Sur1 immuno-
labeling in white matter was widespread and robust
(Fig. 1b, c). Quantitative analysis of Sur1 immunopositiv-
ity confirmed a progressive increase in white matter over
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the course of 30 days post-immunization (Fig. 1e). High
power views showed that Sur1 expression was localized
predominantly to cells with a stellate morphology, consist-
ent with astrocytes (Fig. 1d). Double immunolabeling con-
firmed that Sur1 expression was localized predominantly
to GFAP+ astrocytes (Fig. 1d). Quantitative analysis of the
double immunolabeling data revealed a high degree of co-
localization of Sur1 with GFAP (Pearson’s correlation
coefficient (PCC), 0.78) and minimal co-localization of
Sur1 with microglial Iba1 (PCC, 0.22) and oligodendrocyte
MBP (PCC, 0.04) (Fig. 1f), consistent with most of the
newly upregulated Sur1 being localized to astrocytes.
In gray matter, as in white matter, most of the Sur1
expressed by pid-30 was identified in stellate cells,
consistent with astrocytes, and most NeuN+ neurons
showed little or no detectable Sur1 (Fig. 1g). Rarely, a
“basket” of Sur1 immunopositivity was seen surrounding
a neuron (Fig. 1h).
Double immunolabeling experiments showed that, as
with Sur1, Trpm4 was not detected in normal WT con-
trols, exhibited modest immunopositivity in the white
matter on pid-10, and showed robust labeling in white
matter by pid-30 (Fig. 2a–c, e). Double labeling of tis-
sues from Abcc8−/−/EAE mice showed upregulation of
Trpm4 but no detectable Sur1 (Fig. 2d). As with Sur1,
quantification of Trpm4 immunopositivity confirmed a
progressive increase in white matter over the course of
30 days post-immunization (Fig. 2g).
The merged images of Fig. 2 showed striking co-
localization of Trpm4 with Sur1, with quantitative ana-
lysis confirming a very high degree of co-localization
(PCC, 0.94) (Fig. 1g). This finding suggested that astro-
cytes in WT/EAE mice might be expressing co-
assembled Sur1-Trpm4 channels. To determine whether
Sur1 co-assembled with Trpm4 to form Sur1-Trpm4
channels in EAE, we performed immunoFRET and co-
immunoprecipitation, as previously described [17, 18].
ImmunoFRET imaging demonstrated that Sur1 and
Trpm4 co-assembled (Fig. 2f ). Measurements of FRET
efficiency, when both primary antibodies were present,
yielded values of 10–14 %, compared to ~0 % in negative
controls [17, 18]. Co-immunoprecipitation experiments
were carried out using tissues from pid-30 WT/EAE
mice. These experiments showed that Sur1 was upre-
gulated in EAE compared to controls (Fig. 2h). More im-
portantly, co-assembled Sur1-Trpm4 was undetectable
in controls but was prominent in EAE, confirming the
findings of immunoFRET that Sur1 and Trpm4 co-
assembled in EAE (Fig. 2h).
Glibenclamide and Abcc8−/− in murine EAE
Clinical scoring was assessed daily on pid-0–30. Un-
treated WT/EAE mice showed a typical course of acute
EAE, marked by worsening paralysis scores beginning
on pid-10–13, peaking several days later, then persisting
through pid-30 (Fig. 3a). The mean clinical score for the
disease period (pid-9–30) was 2.34 ± 0.23. The day of
disease onset and the mean clinical scores at different
times during the disease course are shown in Table 1.
Fig. 1 Upregulation of Sur1 in astrocytes in EAE. a–c White matter
of lumbar spinal cord sections from control (CTR) (a) or WT/EAE
mice on pid-10 or pid-30, as indicated (b, c), immunolabeled for
Sur1; all imaging parameters were identical for the three panels;
nuclei stained with DAPI. d Lumbar spinal cord section from a
pid-30 WT/EAE mouse immunolabeled for Sur1 (green; left panel)
and co-labeled for GFAP (red; middle panel) to identify astrocytes;
merged images are also shown (d, right panel). e Box plots showing
the percent of white matter with Sur1 immunopositivity under
control conditions (pid-0) and at pid-10 and pid-30; five mice/group.
f Bar graph showing Pearson’s correlation coefficient for Sur1
co-localization with GFAP, Iba1, and MBP; five mice/group. g, h Gray
matter of lumbar spinal cord section from a pid-30 WT/EAE mouse
double-labeled for Sur1 (red) and co-labeled for NeuN (green) to
identify neurons; merged images are shown. The results illustrated
are representative of findings in five mice/group; scale bars, 100 μm
(a–c); 50 μm (d, g, h)
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Fig. 2 Upregulation of Sur1-Trpm4 channels in astrocytes in EAE. a–e White matter of lumbar spinal cord sections from control (CTR) (a), pid-10
(b), pid-30 (c–e) WT/EAE (b, c, e), and Abcc8−/−/EAE (d) mice, immunolabeled for Sur1 and co-labeled for Trpm4; merged images are shown in
(a–d and e, right panel), demonstrating extensive co-localization (yellow) of Sur1 and Trpm4; secondary antibodies were conjugated with Alexa
Fluoro 488 (green) or Cy3 (red). f Lumbar spinal cord section from a pid-30 WT/EAE mouse, immunolabeled for Sur1 (left panel), and co-labeled for
Trpm4 (middle panel); immunoFRET imaging is also shown (right panel), demonstrating co-assembly of Sur1 and Trpm4; secondary antibodies
were conjugated with Cy3 (red) or Cy5 (purple). g Box plots (left panel) showing the percent of white matter with Trpm4 immunopositivity
under control conditions (pid-0) and at pid-10 and pid-30; bar graph (right panel) showing Pearson’s correlation coefficient for Sur1 and Trpm4
co-localization; five mice/group. h Immunoblot (left panel) showing upregulation of Sur1 in WT/EAE compared to control; HSC-70 used as a
loading control; co-immunoprecipitation (right panel), with immunoisolation performed using anti-Sur1 antibody, and immunoblot performed
using anti-Trpm4 antibody, showing co-assembly of Sur1 and Trpm4 exclusively in EAE. The results illustrated are representative of findings in five
mice/group; scale bars, 100 μm (a–d); 200 μm (e); 50 μm (f)
Fig. 3 Glibenclamide and Abcc8−/− reduce disease severity in EAE. a Mean values of clinical scores following EAE induction for untreated WT/EAE
mice, for glibenclamide-treated WT/EAE mice and Abcc8−/−/EAE mice; glibenclamide treatment was started on pid-10, when >20 % of mice had
clinical scores of 1 or greater; 10 mice/group. b Daily serum glucose for first 4 days in mice receiving no treatment (empty circle) or glibenclamide
treatment (empty diamonds)
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We used the potent Sur1 inhibitor, glibenclamide, to
assess whether Sur1-Trpm4 channels play a role in dis-
ease progression. Mice were injected once daily with
10 μg IP, beginning at the time of disease onset (pid-10)
and continuing through to pid-30. Compared to un-
treated WT/EAE mice, glibenclamide ameliorated the
clinical manifestations of EAE (Fig. 3a). The decrease in
clinical severity in glibenclamide-treated WT/EAE mice
persisted throughout the experiment and manifested a
robust effect size (Cohen’s d, 1.2). The mean clinical
score for the disease period (pid-9–30) was 0.94 ± 0.08,
which was significantly different from that in untreated
WT/EAE mice (Table 1). Notably, the dose of glibencla-
mide used did not induce hypoglycemia (Fig. 3b).
The findings on Sur1-Trpm4 upregulation, com-
bined with the effects observed with glibenclamide,
were consistent with involvement of Sur1. To confirm
functional involvement of Sur1 in EAE, we also stud-
ied Abcc8−/− mice. As with glibenclamide in WT/
EAE mice, Abcc8−/−/EAE mice exhibited a decrease
in clinical severity, compared to untreated WT/EAE
mice, which persisted throughout the experiment and
manifested the same robust effect size as glibenclamide
(Fig. 3a). The mean clinical scores for the disease period
(pid-9–30) was 1.16 ± 0.12, which was significantly differ-
ent from untreated WT/EAE mice but not different from
glibenclamide-treated WT/EAE mice (Table 1).
Glibenclamide and Abcc8−/− reduce the inflammatory
burden in EAE
Sections of lumbar spinal cords from normal WT and
Abcc8−/− controls (without EAE induction), untreated
WT/EAE mice, glibenclamide-treated WT/EAE mice, and
Abcc8−/−/EAE mice at pid-30 were stained with H&E
(Fig. 4). Normal WT controls (Fig. 4a) and Abcc8−/− con-
trols (not shown) were indistinguishable, showing no
constitutive inflammation. Foci of inflammation were ob-
served in the white matter of all untreated EAE spinal
cords (Fig. 4b). Meningeal, perivascular, and parenchymal
inflammatory infiltrates were reduced in the spinal cords
of glibenclamide-treated WT/EAE and Abcc8−/−/EAE
mice, compared to untreated WT/EAE mice (Fig. 4c, d).
Quantification revealed a significant difference in the infil-
trated cell accumulation, 49.7 ± 2.4 % of the quadrants in
the untreated WT/EAE group were positive for inflamma-
tion, compared with 12.7 ± 3.3 % of the quadrants in
glibenclamide-treated WT/EAE mice and 9.4 ± 1.5 % of
the quadrants in Abcc8−/−/EAE mice (Fig. 4e).
To characterize the inflammatory cells present, sections
of lumbar spinal cords were immunolabeled for markers
of leukocytes (CD45), T cells (CD3), B cells (CD20), and
macrophage/microglia (Cd11b). Inflammatory lesions in
untreated WT/EAE lumbar spinal cords contained signifi-
cantly increased numbers of CD45+, CD3+, CD20+, and
CD11b+ cells, compared to normal controls (Fig. 4a, b, e).
The number of inflammatory cells in glibenclamide-
treated WT/EAE and Abcc8−/−/EAE lumbar spinal cords
was significantly reduced, compared to untreated WT/
EAE spinal cords (Fig. 4c–e).
To further characterize the effect of Sur1 inhibition or
deletion on immune modulation in vivo, we counted
cells positive for the pro-inflammatory cytokines TNF-α,
IFN-γ, and IL-17, all of which were identified in white
matter of lumbar spinal cord sections. Cells expressing
TNF-α, IFN-γ, and IL-17 were significantly increased in
untreated WT/EAE mice compared to normal controls
(Fig. 5a, b, e). Cells expressing TNF-α, IFN-γ, and IL-17
were significantly decreased in glibenclamide-treated
WT/EAE and Abcc8−/−/EAE mice, compared to untreated
WT/EAE mice (Fig. 5c–e).
Glibenclamide and Abcc8−/− reduce demyelination and
promote remyelination in EAE
Spinal cord myelin was stained using Luxol fast blue
(LFB) and was immunolabeled for myelin basic protein
(MBP) [32] (Fig. 6). White matter tracts in untreated
WT/EAE mice stained weakly with LFB and labeled
weakly for MBP. Compared to normal controls, the spinal
cords of untreated WT/EAE mice showed 46 ± 1 % de-
myelination by LFB and 38 ± 1.9 % by MBP, whereas the








Day 15b Day 20c Day 25c Day 30c Day 9–30d
WT/EAE 10/10 (100) 2 11.8 ± 0.36 2.1 ± 0.38 3.1 ± 0.46 3.0 ± 0.45 3.1 ± 0.48 2.34 ± 0.23
WT/EAE + GLIB 10/10 (100) 1 12.9 ± 0.50 1.3 ± 0.34 1.0 ± 0.34 1.0 ± 0.33 1.1 ± 0.35 0.94 ± 0.08
Abcc8−/−/EAE 10/10 (100) 0 13.0 ± 0.41 1.8 ± 0.36 1.4 ± 0.31 1.3 ± 0.26 1.0 ± 0.29 1.16 ± 0.12
Values are presented as mean ± SEM (10 mice per group)
aDisease onset is defined as the first day of a clinical score of one or more. There was no statistically significant difference in day of onset of disease between
the groups
bThere was no statistically significant difference in scores between the groups on day 15
cOn day 20, 25, and 30, the mean clinical scores of mice were significantly lower in WT/EAE + GLIB and Abcc8−/−/EAE groups compared to WT/EAE group. (For all
three time points: WT/EAE vs. WT/EAE + GLIB, P < 0.01; WT/EAE vs. Abcc8−/−/EAE, P < 0.01; N = 10; one-way ANOVA with Fisher’s post-hoc comparisons)
dOverall Mean score during the disease phase (Day 9 to 30) is significantly lower in WT/EAE + GLIB and Abcc8−/−/EAE groups compared to WT/EAE group. (WT/EAE vs.
WT/EAE + GLIB, P < 0.001; WT/EAE vs. Abcc8−/−/EAE, P < 0.001; N = 10; one-way ANOVA with Fisher’s post-hoc comparisons)
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spinal cords of glibenclamide-treated WT/EAE mice
showed 11 ± 2 % demyelination by LFB and 12.1 ± 0.5 %
by MBP, and those of Abcc8−/−/EAE mice showed 9.7 ±
1.1 % demyelination by LFB and 11.1 ± 1.1 % by MBP.
Expression of the mature oligodendrocyte marker,
CNPase, verified the data on MBP (Fig. 6). Compared to
normal controls, 51 ± 0.4 % of the quadrants in un-
treated EAE mice showed loss of staining, compared
to 4.5 ± 1.0 % of the quadrants in glibenclamide-
treated WT/EAE mice and 4.2 ± 0.8 % of the quadrants in
Abcc8−/−/EAE mice.
We also performed counts of cells positive for Olig-2,
a marker of oligodendrocytes, and PDGFR-α, a marker
of oligodendrocyte precursor cells (OPC) (Fig. 6). Olig-2+
but not PDGFR-α+ cells were significantly increased in
WT/EAE, while cells with both markers were significantly
increased in both glibenclamide-treated WT/EAE and in
Abcc8−/−/EAE, consistent with increased proliferation of
OPC with treatment.
Glibenclamide and Abcc8−/− protect against axonal
damage
To assess for axonal sparing, spinal cords were examined
using the pan-axonal neurofilament marker, anti-SMI 312,
as well as silver nitrate staining (Fig. 7). For SMI 312 and
silver nitrate, respectively, quantification revealed axonal
Fig. 4 Glibenclamide and Abcc8−/− suppress immune cell infiltration in EAE. a–d White matter of lumbar spinal cord sections from WT control
(a), untreated pid-30 WT/EAE (b), glibenclamide-treated pid-30 WT/EAE (c), and pid-30 Abcc8−/−/EAE (d) mice, stained with H&E or immunolabeled
for CD45 (leucocyte), CD3 (T cells), CD20 (B cells), or CD11b (macrophage/microglia), as indicated; original magnification, ×200 (H&E) or ×400
(all immunolabelings). e left panel: percent of quadrants with inflammatory cells on H&E; four mice/group. e four right panels: Quantification of CD-45-,
CD3-, CD20-, and CD11b-expressing cells in white matter; four mice/group; ##P < 0.01 with respect to WT control; **P < 0.01, and ***P < 0.001 with
respect to WT/EAE; scale bars, 100 μm
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losses of 58.7 ± 5.3 % and 48.5 ± 1 % in untreated WT/
EAE mice, compared to normal controls, versus losses
of 7.7 ± 3.2 % and 4.9 ± 0.5 % in glibenclamide-treated
WT/EAE mice and 1.4 ± 0.4 % and 4.3 ± 0.4 % in
Abcc8−/−/EAE mice.
Discussion
The major findings of the present study are that in EAE
(i) Sur1 and Trpm4 are progressively upregulated between
pid-10 and pid-30, (ii) Sur1 and Trpm4 co-assemble to
form Sur1-Trpm4 channels, (iii) the dominant cell type
that expresses Sur1-Trpm4 is the astrocyte, and (iv) dele-
tion as well as pharmacological blockade of Sur1 yields
robust neurological protection in EAE.
The clinical course and severity of EAE were signifi-
cantly ameliorated in WT/EAE mice administered gliben-
clamide beginning at the time of disease onset (pid-10) as
well as in Abcc8−/−/EAE mice. On pid-30, the lumbar
spinal cords of WT/EAE mice treated with glibenclamide
and of Abcc8−/−/EAE mice showed a significantly reduced
inflammatory burden, including fewer inflammatory le-
sions (H&E), fewer invading peripheral immune cells,
including leukocytes (CD45), T cells (CD3), B cells (CD20)
and macrophages/microglia (CD11b), and fewer cells
expressing pro-inflammatory cytokines (TNF-α, IFN-γ, IL-
17). The reduced inflammatory burden with glibenclamide
and Abcc8 deletion correlated with better preservation of
myelin (LFB, MBP), better preservation of axons (silver
Fig. 5 Glibenclamide and Abcc8−/− alter the cytokine profile in EAE. a–d White matter of lumbar spinal cord sections from WT control (a),
untreated pid-30 WT/EAE (b), glibenclamide-treated pid-30 WT/EAE (c), and pid-30 Abcc8−/−/EAE (d) mice, immunolabeled for TNFα, IFN-γ, or
IL-17, as indicated; original magnification, ×400. e Quantification of TNFα-, IFN-γ-, and IL-17-expressing cells in white matter; four mice/group;
##P < 0.01 and ###P < 0.001 with respect to WT control; *P < 0.05, **P < 0.01, and ***P < 0.001 with respect to WT/EAE; scale bars, 100 μm
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nitrate, SMI-312), and more numerous mature and pre-
cursor oligodendrocytes (CNPase, Olig-2, PDGFR-α).
Glibenclamide and Abcc8 deletion also increased the
density of CNPase as well as MBP, which are markers of
mature OLs in vivo. The improved myelination with glib-
enclamide and Abcc8 deletion may have resulted from an
enhanced number of OPCs differentiating into myelinat-
ing OLs, as these treatments increased the numbers and
promoted the maturation of myelinating cells.
Schattling et al. [20] were the first to report the effect
of glibenclamide in a murine MOG35–55 model of EAE.
In their report, Schattling et al. attributed the beneficial
effects of glibenclamide to blockade of Trpm4. However,
the present study casts doubt on their interpretation that
Trpm4 is the direct target of glibenclamide in EAE. First,
we show here that Trpm4 upregulation is accompanied
by upregulation of Sur1 and by co-assembly of Trpm4
with Sur1 to form Sur1-Trpm4 heteromers. It is known
that glibenclamide is much more potent as a blocker of
Sur1-Trpm4 than of Trpm4 alone—the EC50 for glib-
enclamide blockade of Sur1-Trpm4 is 48 nM, and
both native and recombinant Sur1-Trpm4 channels
are blocked >90 % by 1 μM [17, 33]. By contrast, with
Trpm4 alone, the EC50 for glibenclamide may be as high
Fig. 6 Glibenclamide and Abcc8−/− promote remyelination in EAE. a–d White matter of lumbar spinal cord sections from WT control (a),
untreated pid-30 WT/EAE (b), glibenclamide-treated pid-30 WT/EAE (c), and pid-30 Abcc8−/−/EAE (d) mice, stained with Luxol fast blue (LFB) or
immunolabeled for MBP (myelin), CNPase, Olig2 (oligodendrocytes), or PDGFR-α (oligodendrocyte progenitor cells (OPC)), as indicated; nuclei
stained with DAPI in the MBP sections; original magnification, ×200 (LFB) or ×400 (all immunolabelings). e three left panels: Percent of quadrants
with myelin loss by LFB staining, by MBP immunolabeling, or by CNPase immunolabeling. e two right panels: Quantification of Olig-2-expressing
cells in white matter or of PDGFR-α-expressing OPC near the central canal; four mice/group; ##P < 0.01 and ###P < 0.001 with respect to WT control;
***P < 0.001 with respect to WT/EAE; scale bars, 100 μm
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as 100 μM [34], and 1 μM results in <10 % blockade [17].
The dose of glibenclamide administered by Schattling et
al., as well as by us in the present report, was 10 μg per
mouse, ~0.4 mg/kg, daily. In rodents, this dose yields peak
serum levels of ~120 nM [35, 36], which is far below that
required to block Trpm4 alone but is adequate for block-
ade of Sur1-Trpm4. Second, the observations that (i)
protection by Abcc8 deletion is indistinguishable from
protection by glibenclamide and (ii) in Abcc8−/− mice,
Trpm4 was upregulated yet appeared to be harmless in
the absence of Sur1, not only confirmed functional in-
volvement of Sur1 in EAE but also is most consistent with
the hypothesis that protection with glibenclamide is due
to Sur1 inhibition, not Trpm4 inhibition.
Apart from blockade of Sur1-regulated channels, glib-
enclamide exhibits other actions that could potentially
contribute to the salutary effects observed here and pre-
viously [20]. Glibenclamide is known to block the
NLRP3 (NACHT, LRR, and PYD domains-containing
protein 3) inflammasome, which has been implicated in
the pathophysiology of EAE [37]. However, given the
high dose of glibenclamide required to block the inflam-
masome (EC50, ~75 μM) [38], it is unlikely that this
mechanism was involved in the beneficial effect of glib-
enclamide in EAE. Glibenclamide also acts as a PPARγ
(peroxisome proliferator-activated receptor γ) agonist
[39], a class of drugs with favorable effects in CNS in-
flammation, including EAE [40, 41]. However, glibencla-
mide’s efficacy as a PPARγ agonist is only ~20 % that of
pioglitazone [39]. Importantly, since neither the NLRP3
inflammasome nor PPARγ involves Sur1, and since dele-
tion of Abcc8 mimicked the effect of glibenclamide, the
involvement of either of these mechanisms is highly un-
likely. Overall, our data indicate that Sur1-Trpm4 is the
most likely target of glibenclamide in EAE.
An important property of the Sur1-Trpm4 channel is
that both subunits, Sur1 and Trpm4, are required for
the manifestation of its pathological effects. This pathog-
nomonic property previously was best exemplified in
traumatic spinal cord injury, where pharmacological
blockade of Sur1 (glibenclamide, repaglinide) or of Trpm4
(flufenamic acid, riluzole), gene suppression (antisense
oligodeoxynucleotide against Abcc8 or Trpm4), and gene
deletion (Abcc8−/− or Trpm4−/−), all were shown to re-
sult in the exactly the same phenotype—reduced micro-
vascular dysfunction and capillary fragmentation [24]. Our
present data, combined with those of Schattling et al. [20],
extend observations based on traumatic spinal cord injury,
showing that in EAE as well, deletion of Abcc8 or of
Trpm4 results in the same phenotype—reduced inflamma-
tion and better preservation of myelin, better preservation
of axons, and more numerous mature and precursor
oligodendrocytes.
Schattling et al. [20] showed that immune cell infiltra-
tion, measured on pid-15, was not affected by glibencla-
mide treatment beginning on pid-8. By contrast, we
found a significant reduction in immune cell infiltrates
with glibenclamide when tissues were studied on pid-30.
Apart from being performed much earlier, the cell
counts reported by Schattling et al. [20] were based on
the entire CNS (brain and spinal cord), whereas our cell
counts were based on the lumbar spinal cord alone,
Fig. 7 Glibenclamide and Abcc8−/− protect against axonal damage.
a–d White matter of lumbar spinal cord sections from WT control
(a), untreated pid-30 WT/EAE (b), glibenclamide-treated pid-30 WT/
EAE (c), and pid-30 Abcc8−/−/EAE (d) mice, immunolabeled for
SMI-312 (neurofilament marker) or stained with silver nitrate, as
indicated; original magnification, ×400. e Percent of quadrants with
axonal loss by SMI-132 labeling and by silver nitrate staining; four
mice/group; ##P < 0.01 and ###P < 0.001 with respect to WT control;
***P < 0.001 with respect to WT/EAE; scale bars, 100 μm
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where the pathological manifestations of EAE are the
greatest [31]. It could be that, in the Schattling study,
counting invading immune cells in the larger volume of
tissue, most of which likely was unaffected at pid-15,
inadvertently masked elevated numbers in the lumbar
spinal cord.
Schattling et al. [20] reported significantly more
Trpm4-positive axons in EAE mice compared to con-
trols, based on morphology showing labeling of small
round structures. Surprisingly, Schattling et al. did not
report Trpm4 expression in astrocytes, whereas our data
showed robust expression of Sur1-Trpm4 in astrocytes
in EAE. These apparent differences are almost certainly
due to the different times at which tissues were evalu-
ated after disease induction. Schattling et al. studied tis-
sues on pid-14—our data showed minimal expression on
pid-10 but robust expression by pid-30. It is not surpris-
ing that astrocytes would express Sur1 and Trpm4, since
this is the cell type in which the Sur1-Trpm4 channel
was first discovered [33] and in which it has been repeat-
edly shown to be upregulated post-injury [17, 18, 42].
Notably, in cerebral ischemia, expression by astrocytes
also increases slowly, reaching a maximum only after
1 month [29].
The prominent expression of Sur1-Trpm4 by astro-
cytes suggests that astrocytic Sur1-Trpm4 channels may
be a principal target of glibenclamide. There is emerging
recognition of a critical role of astrocytes as immune ef-
fector cells with an essential role in EAE [43–46]. Acti-
vation of astrocytes in EAE occurs at the onset of the
acute clinical episode, with the intensity being a good
predictor of the clinical severity in animal models [47].
Astrocytes are the first cells in the CNS to be acti-
vated by MOG-reactive T cells and to synthesize pro-
inflammatory cytokines and chemokines that are essential
for the induction of EAE [48]. As active players in CNS
innate immunity, astrocytes participate actively and differ-
ently at different stages of the pathologic process [43]. As-
trocytes contribute mechanistically to lesion development
in EAE by (i) modifying blood–brain barrier properties
and up-regulating adhesion molecules and matrix metallo-
proteases required for leukocyte invasion, (ii) expressing
cytokines and chemokines that attract leukocytes, (iii) pro-
ducing factors toxic to oligodendrocytes and neurons, and
(iv) blocking the maturation of oligodendrocyte precursor
cells.
Important questions remain about Sur1-Trpm4 in
EAE. Although the Sur1-Trpm4 channel in astrocytes
has been characterized [33, 49], the role of the channel
in astrocyte function in EAE remains to be determined.
It is known that the channel acts principally as a nega-
tive regulator of calcium influx, with block of the chan-
nel by glibenclamide promoting increased calcium influx
[17, 50]. Astrocytes secrete pro-inflammatory cytokines
and chemokines that are essential for the induction of
EAE [48, 51]. It may be that Sur1-Trpm4 blockade by
glibenclamide alters calcium signaling in astrocytes and
thereby impairs their secretion of pro-inflammatory cy-
tokines and chemokines. Additional work, including
astrocyte-specific deletion of Sur1-Trpm4 in EAE, will
be required to fully elucidate the role of astrocytic Sur1-
Trpm4 channels in the pathogenesis of EAE.
Conclusions
The Sur-Trpm4 channel is newly upregulated in murine
EAE. Given its prominent expression in reactive astro-
cytes, and the important pro-inflammatory role of astro-
cytes in MS and EAE, the Sur1-Trpm4 channel may
represent a novel therapeutic approach for disease modi-
fication to reduce peripheral immune cell entry into the
CNS without compromising the function of peripheral
immune cells themselves.
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